Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | May 23, 2023 | May 24, 2023 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | January 11, 2021 | January 13, 2021 |
| GERON CORPGERN · Entity 4989 | Director | May 21, 2025 | May 22, 2025 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | September 26, 2018 | September 27, 2018 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 07, 2022 | June 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 23, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,140 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Grant · Acquired 4,190 · Balance 33,140 F1: Restricted stock units granted on May 23, 2023. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on May 23, 2023. Price not applicable.
Coherus Oncology, Inc.
Report date January 11, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2031-01-11 | Direct | 20,000 |
Reported balance
After 2021-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-11 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
GERON CORP
Report date May 21, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2035-05-20 | Direct | 180,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 180,000 · Balance 180,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
SUTRO BIOPHARMA, INC.
Report date September 26, 2018 · Filed September 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2028-09-25 | Direct | 26,033 |
Reported balance
After 2018-09-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-26 · Grant · Acquired 26,033 · Balance 26,033 F1: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.
Spyre Therapeutics, Inc.
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2032-06-06 | Direct | 43,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 43,000 · Balance 43,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2025 Filed May 22, 2025 21:04 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000886744-25-000025 · wk-form4_1747947876.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:20 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 13,300 | $1.18 | $15,667.40 |
DisclosureSEC source: 0000886744-25-000013 · wk-form4_1747167635.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0000950170-24-061615 · ownership.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2024-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 20, 2024, and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 14, 2024. F3 · derivative.exercise_date: Option was fully vested. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 35,000 | $3.75 | $131,250.00 |
DisclosureSEC source: 0000950170-24-061615 · ownership.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 20, 2024, and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 14, 2024. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.715 to $3.790, inclusive. The reporting person undertakes to provide to Geron Corporation, any security holder of Geron Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 35,000 | $1.94 | $67,900.00 |
DisclosureSEC source: 0000950170-24-061615 · ownership.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 20, 2024, and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 14, 2024. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-057795 · ownership.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:32 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012815 · form4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 23, 2023 Filed May 24, 2023 22:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031973 · doc4.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,140 F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable. Read SEC document |
| May 11, 2023 Filed May 12, 2023 01:01 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Options (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001062993-23-010852 · form4.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 6, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| May 11, 2023 Filed May 12, 2023 01:01 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 35,000 | $3.00 | $105,000.00 |
DisclosureSEC source: 0001062993-23-010852 · form4.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 6, 2023. Read SEC document |
| May 11, 2023 Filed May 12, 2023 01:01 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 35,000 | $1.10 | $38,500.00 |
DisclosureSEC source: 0001062993-23-010852 · form4.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 6, 2023. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 8,500 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-023062 · doc4.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 29, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 8,500 | $97.09 | $825,265.00 |
DisclosureSEC source: 0001209191-23-023062 · doc4.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,950 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 29, 2022. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,500 | $67.81 | $576,385.00 |
DisclosureSEC source: 0001209191-23-023062 · doc4.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 29, 2022. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-035685 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 24, 2022 Filed May 27, 2022 01:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011796 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,950 F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:16 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-22-012155 · form4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 00:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,250 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-008633 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,250 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on July 29, 2021. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 00:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,250 | $83.66 | $355,555.00 |
DisclosureSEC source: 0001567619-22-008633 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,970 F1 · date: Trade made pursuant to a 10b5-1 plan executed on July 29, 2021. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 00:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,250 | $37.46 | $159,205.00 |
DisclosureSEC source: 0001567619-22-008633 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on July 29, 2021. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,250 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-001334 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on July 29, 2021. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,250 | $87.61 | $372,342.50 |
DisclosureSEC source: 0001567619-22-001334 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,970 F1 · date: Trade made pursuant to a 10b5-1 plan executed on July 29, 2021. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,250 | $37.46 | $159,205.00 |
DisclosureSEC source: 0001567619-22-001334 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on July 29, 2021. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 17:23 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-039226 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 23:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011314 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,970 F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable. Read SEC document |
| May 11, 2021 Filed May 14, 2021 01:16 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000886744-21-000035 · edgar.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2031-05-10 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 7,500 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001567619-21-008291 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020, as amended on August 21, 2020. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,500 | $76.90 | $576,750.00 |
DisclosureSEC source: 0001567619-21-008291 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020, as amended on August 21, 2020. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,500 | $26.49 | $198,675.00 |
DisclosureSEC source: 0001567619-21-008291 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020, as amended on August 21, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 7,500 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001567619-21-004470 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020, as amended on August 21, 2020. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,500 | $87.41 | $655,575.00 |
DisclosureSEC source: 0001567619-21-004470 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020, as amended on August 21, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,500 | $26.49 | $198,675.00 |
DisclosureSEC source: 0001567619-21-004470 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020, as amended on August 21, 2020. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:25 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000984 · doc1.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 16:24 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 28,100 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0001209191-20-035515 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires 2030-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2020 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:12 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000886744-20-000049 · edgar.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,430 | $107.46 | $476,047.80 |
DisclosureSEC source: 0001567619-20-011919 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020. Read SEC document |
| May 27, 2020 Filed May 29, 2020 21:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011362 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,280 F1 · price: Restricted stock units granted on May 27, 2020. Price not applicable. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,750 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-20-006723 · doc1.xml · derivative · entry 4 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. F3 · balance_after: Reflects the number of options outstanding after the transactions from the specific stock option grant. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $75.39 | $282,712.50 |
DisclosureSEC source: 0001567619-20-006723 · doc1.xml · nonDerivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,980 F2 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $21.51 | $80,662.50 |
DisclosureSEC source: 0001567619-20-006723 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| March 16, 2020 Filed Mar 19, 2020 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,610 | $76.52 | $352,757.20 |
DisclosureSEC source: 0001567619-20-006723 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,980 F1 · date: Trade made pursuant to a 10b5-1 plan executed on January 16, 2020. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:52 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001044 · doc1.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 17, 2019 Filed Dec 20, 2019 01:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,750 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-19-023466 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. F2 · balance_after: Reflects the number of options outstanding after the transactions from the specific stock option grant. Read SEC document |
| December 17, 2019 Filed Dec 20, 2019 01:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $83.36 | $312,600.00 |
DisclosureSEC source: 0001567619-19-023466 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,590 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| December 17, 2019 Filed Dec 20, 2019 01:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $21.51 | $80,662.50 |
DisclosureSEC source: 0001567619-19-023466 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 22:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,750 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-19-018505 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 3,750 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. F2 · balance_after: Reflects the number of options outstanding after the transactions from the specific stock option grant. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 22:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $74.47 | $279,262.50 |
DisclosureSEC source: 0001567619-19-018505 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,590 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 22:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $21.51 | $80,662.50 |
DisclosureSEC source: 0001567619-19-018505 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,750 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-19-013660 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 3,750 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. F2 · balance_after: Reflects the number of options outstanding after the transactions from the specific stock option grant. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 16:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $81.08 | $304,050.00 |
DisclosureSEC source: 0001567619-19-013660 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,590 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.